The Effect of Olive Leaf Extract Supplementation on Training-induced Skeletal Muscle Functional and Molecular Adaptations in Healthy Volunteers (OLE_Training_1)
22. juli 2026 opdateret af: Nicolas Place, University of Lausanne
The goal of this study is to investigate the effect of combining olive leaf extract supplementation with endurance training (moderate intensity continuous training or sprint interval training).
We hypothesize that OLE supplementation during training, as compared to training alone with placebo, will translate into better performance outcomes.
More specifically, we hypothesize that the additional benefits of OLE supplementation on performance will be mediated by improved mitochondrial characteristics in skeletal muscle and increased neural activation.
Studieoversigt
Status
Ikke rekrutterer endnu
Intervention / Behandling
Detaljeret beskrivelse
Maximal exercise capacity (VO2peak) predicts cardiovascular risk and all-cause mortality.
Regular moderate to vigorous physical activity, a key determinant of VO2peak, is essential for an optimal health status of the general population.
Thus, strategies that accentuate the health benefits of exercise may have considerable therapeutic benefits.
Skeletal muscle Ca2+ handling is a primary determinant of exercise capacity.
The regulation of skeletal muscle contraction by Ca2+ is coupled to mitochondrial energy production through a mechanism involving transport across the inner mitochondrial membrane by the mitochondrial Ca2+ uniporter (MCU).
Ca2+ entry in the mitochondrial matrix controls Ca2+ -sensitive enzymes, including pyruvate dehydrogenase (PDH) activity, a rate-limiting enzyme for glycolysis.
Olive leaf extract (OLE) contains ~40% of the natural polyphenol oleuropein and is a potent activator of MCU in skeletal muscle with anti-inflammatory and antioxidant properties.
The present study will be a double-blind, randomized, placebo-controlled, parallel study in healthy young individuals (18-45 years) consisting of a 3-week endurance training (either moderate intensity continuous training or sprint interval training) period combined with OLE or placebo intake.
We will examine the impact of OLE supplementation on maximal exercise capacity, knee extensor neuromuscular function, muscular and blood adaptations.
The results of this study will elucidate whether OLE supplementation improves fitness parameters and the molecular mechanisms regulating these adaptations.
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
60
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Nicolas Place, PhD
- Telefonnummer: +41216923806
- E-mail: nicolas.place@unil.ch
Studiesteder
-
-
-
Lausanne, Schweiz, 1015
- Bâtiment Synathlon, quartier UNIL-Centre
-
Kontakt:
- Nicolas Place, PhD
- Telefonnummer: +41216923806
- E-mail: nicolas.place@unil.ch
-
Underforsker:
- Javier Botella, PhD
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Being between 18 and 45 years old
- Being healthy (assessed through the PAR-Q questionnaire).
- Being physically active, but not involved in any structured training program
- Being available for the study period.
Exclusion Criteria:
- If a participant answers positively to any YES/NO question in the PAR-Q health questionnaire. For questions requiring a precision, any positive answer will be reviewed by a medical doctor, who will determine the inclusion/exclusion of the participant.
- Having allergy to xylocaine
- Being pregnant.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Sprint interval training group (SIT group)
The model of sprint interval training (SIT) consists of four to six 30 s all-out cycling bouts on a cycle ergometer, with 4 min rests between tests.
Three sessions will be performed per week for three weeks.
|
A capsule containing 250 mg of an olive leaf extract preparation will be swallowed with a glass of water daily for 21 days.
A capsule containing 336 mg of cellulose microcrystalline will be swallowed with a glass of water daily for 21 days.
|
|
Eksperimentel: Moderate intensity continuous training (MICT group)
The moderate intensity continuous training (MICT) consists of 40 to 60 min cycling on a cycle ergometer at 50% of the maximal aerobic power output.
Three sessions will be performed per week for three weeks.
|
A capsule containing 250 mg of an olive leaf extract preparation will be swallowed with a glass of water daily for 21 days.
A capsule containing 336 mg of cellulose microcrystalline will be swallowed with a glass of water daily for 21 days.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
maximal aerobic power
Tidsramme: before and after the three-week training period
|
maximal power (in watts) measured during a graded exercise to failure
|
before and after the three-week training period
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximal oxygen uptake
Tidsramme: before and after the three-week training period
|
maximal oxygen uptake (ml/min/kg) measured during a graded exercise until failure
|
before and after the three-week training period
|
|
Submaximal heart rate and power
Tidsramme: before and after the three-week training period
|
heart rate and power measured during submaximal cycling exercise
|
before and after the three-week training period
|
|
Knee extensor neuromuscular function
Tidsramme: before and after the three-week training period
|
maximal voluntary contraction force and maximal voluntary activation level
|
before and after the three-week training period
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Zanou N, Dridi H, Reiken S, Imamura de Lima T, Donnelly C, De Marchi U, Ferrini M, Vidal J, Sittenfeld L, Feige JN, Garcia-Roves PM, Lopez-Mejia IC, Marks AR, Auwerx J, Kayser B, Place N. Acute RyR1 Ca2+ leak enhances NADH-linked mitochondrial respiratory capacity. Nat Commun. 2021 Dec 10;12(1):7219. doi: 10.1038/s41467-021-27422-1.
- Gherardi G, Weiser A, Bermont F, Migliavacca E, Brinon B, Jacot GE, Hermant A, Sturlese M, Nogara L, Vascon F, De Mario A, Mattarei A, Garratt E, Burton M, Lillycrop K, Godfrey KM, Cendron L, Barron D, Moro S, Blaauw B, Rizzuto R, Feige JN, Mammucari C, De Marchi U. Mitochondrial calcium uptake declines during aging and is directly activated by oleuropein to boost energy metabolism and skeletal muscle performance. Cell Metab. 2025 Feb 4;37(2):477-495.e11. doi: 10.1016/j.cmet.2024.10.021. Epub 2024 Nov 26.
- Lanfranchi C, Moreno-Asso A, Horstman AMH, Mistro S, Migliavacca E, Cominetti O, Stolte J, Metairon S, Hermant A, Pedersen AL, Dayon L, De Marchi U, Feige JN, Zanou N, Place N. Oleuropein-based olive leaf extract enhances muscle mitochondrial bioenergetics response to moderate - but not maximal - intensity exercise in humans. J Physiol. 2026 May;604(10):3802-3824. doi: 10.1113/JP290316. Epub 2026 Apr 14.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
1. september 2026
Primær færdiggørelse (Anslået)
31. december 2028
Studieafslutning (Anslået)
31. december 2029
Datoer for studieregistrering
Først indsendt
17. juli 2026
Først indsendt, der opfyldte QC-kriterier
22. juli 2026
Først opslået (Faktiske)
27. juli 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
27. juli 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
22. juli 2026
Sidst verificeret
1. juli 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2026-00654
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
UBESLUTET
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .